Xarelto Lawsuit Plaintiffs Alleging Drug Causes Dangerous Bleeding Risks Look Ahead To Early 2017 Bellwether Trials

March 18, 2016 – – BloodThinnerHelp.com reports on the announcement of bellwether trial dates for plaintiffs involved in Xarelto bleeding lawsuits consolidated in MDL 2592. The bellwether trials will consist of 4 specifically selected representative cases and will be heard in early 2017. The MDL is made up of federally-filed Xarelto lawsuits which were consolidated by the U.S. Judicial Panel on Multidistrict Litigation. The litigation surrounding these cases is being overseen by the Honorable Judge Eldon Fallon in the Eastern District of Louisiana.

Documents from the court have indicated that the first two bellwether trials will be held in the Eastern District of Louisiana where the MDL is housed, and are currently scheduled to be heard on February 6th and March 13th of 2017. At this time, the following (and final) two bellwether trials are scheduled to take place in different locations on April 24th and May 30th of 2017.

When first approved by the U.S. Food and Drug Administration, Xarelto was incredibly popular as a new-generation blood thinner which could provide users with freedoms that traditional blood thinners had been unable to. Today, however, the anticoagulant has become the subject of thousands of lawsuits from across the country which continue to grow in number. These lawsuits are being filed by plaintiffs who similarly allege that the anticoagulant places those who take it at elevated risk for spontaneous and dangerous bleeding events.

Xarelto has been linked to gastrointestinal bleeding, blood clots, strokes, brain hemorrhages, and eye bleeds by plaintiffs and recent studies. In certain cases, plaintiffs filing lawsuits are doing so on behalf of loved ones who passed away from severe bleeding episodes. These plaintiffs are in agreement that the defendants, (Xarelto manufacturers Bayer AG and Johnson & Johnson subsidiary Janssen Pharmaceuticals), neglected to properly warn patients and medical professionals about the possible risks which are associated with their product.

2017 bellwether trials will be conducted in order to help provide everyone involved with more concrete ideas concerning how juries may respond to specific testimony or pieces of evidence when presented during future trials. Those involved anticipate that, as they await 2017 bellwether hearings, other Xarelto lawsuits will continue to be filed. Currently, the MDL includes over 2,800 cases, and these are additionally joined by a mass tort program of more than 600 Xarelto lawsuits in Philadelphia, Pennsylvania formed by the Court of Common Pleas.

Attorney Joseph Osborne is working to help ensure that anyone who believes that they suffered health problems from their use of Xarelto will be provided the important opportunity to explore their legal rights fully. These patients could be entitled to substantial compensation through legal action. To help those wishing to pursue justice in the matter, Attorney Osborne is offering complimentary Xarelto consultations for affected parties at this time.

To request additional information or ask questions, please contact Joseph Osborne, Esq. at (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008779